BridgeBio Pharma Inc
BBIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.55B
Close$
$-76.74
194.5% downside
Current Fair Value
194.5% downsideOvervalued by 194.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $16.55 Billion |
|---|---|
| Enterprise Value | $18.37 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.79 |
| Beta | 0.95 |
| Outstanding Shares | 194,789,897 |
Return
| Return on Equity | 27.68% |
|---|---|
| Return on Assets | -57.20% |
| Return on Invested Capital | -186.30% |
Valuation & Multiples
| P/E Ratio | -22.53 |
|---|---|
| PEG | 138.04 |
| Price to Sales | 27.07 |
| Price to Book Ratio | -6.25 |
| Enterprise Value to Revenue | 27.09 |
| Enterprise Value to EBIT | -30.18 |
| Enterprise Value to Net Income | -27 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | -0.99 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.58
Average shareholder expectationRevenue Estimate
$220.91 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.49
Average shareholder expectationRevenue Estimate
$251.96 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.2521▲ 110.17% |
|---|---|
| Total Calls | 209,400▼ 97.98% |
| Total Puts | 262,200▼ 83.20% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 11.78%▼ 88.14% |
|---|---|
| Total Invested | $1.71B▼ 88.15% |
| Investors Holding | 199▼ 292.00% |
ESG Score
No data
About BridgeBio Pharma Inc
CEO: Neil Kumar